Market Research Logo

West Nile Virus Infections - Pipeline Review, H2 2015

West Nile Virus Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘West Nile Virus Infections - Pipeline Review, H2 2015’, provides an overview of the West Nile Virus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for West Nile Virus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the West Nile Virus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the West Nile Virus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
West Nile Virus Infections Overview
Therapeutics Development
Pipeline Products for West Nile Virus Infections - Overview
Pipeline Products for West Nile Virus Infections - Comparative Analysis
West Nile Virus Infections - Therapeutics under Development by Companies
West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes
West Nile Virus Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
West Nile Virus Infections - Products under Development by Companies
West Nile Virus Infections - Products under Investigation by Universities/Institutes
West Nile Virus Infections - Companies Involved in Therapeutics Development
BioDiem Ltd
CalAsia Pharmaceuticals, Inc.
CEL-SCI Corporation
Kineta, Inc.
Nanotherapeutics, Inc.
West Nile Virus Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BG-323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETX-112 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HydroVax-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Innate Immune Adjuvants - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RL-14C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RL-15A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rOAS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize IRF-3 for Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for West Nile Virus and Dengue Virus Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
west nile virus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
west nile virus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
West Nile virus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
West Nile Virus Infections - Recent Pipeline Updates
West Nile Virus Infections - Dormant Projects
West Nile Virus Infections - Product Development Milestones
Featured News & Press Releases
Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for West Nile Virus Infections, H2 2015
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
West Nile Virus Infections - Pipeline by BioDiem Ltd, H2 2015
West Nile Virus Infections - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015
West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H2 2015
West Nile Virus Infections - Pipeline by Kineta, Inc., H2 2015
West Nile Virus Infections - Pipeline by Nanotherapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
West Nile Virus Infections Therapeutics - Recent Pipeline Updates, H2 2015
West Nile Virus Infections - Dormant Projects, H2 2015
West Nile Virus Infections - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for West Nile Virus Infections, H2 2015
Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report